Novo Nordisk wins appeal over claims that diabetes drug causes cancer – Reuters.com

Scanpix Denmark/Liselotte Sabroe via REUTERS
(Reuters) – A federal appeals court declined to revive claims that Novo Nordisk's Type 2 diabetes drug Victoza can cause pancreatic cancer.
A unanimous panel of the 9th U.S. Circuit Court of Appeals ruled Monday that U.S. District Judge Anthony Battaglia, who presided over a multidistrict litigation over similar diabetes drugs made by Novo Nordisk and other companies, did not abuse his discretion in excluding the plaintiffs' sole expert on the drug's alleged cancer link, Robert Gale.
The panel wrote that Gale was "alone" in the scientific community in his view that Victoza causes cancer, and that he admittedly did not independently review studies published since 2015 finding no link, supporting Battaglia's March 2021 ruling granting summary judgment to Novo Nordisk.
The company said in a statement that it was pleased by the ruling and continued to "firmly stand behind the safety of Victoza."
The drug brought the company about $2.2 billion in revenue in 2021, out of total sales of $16.8 billion, according to its annual report.
Timothy Becker of Johnson Becker, a lawyer for the plaintiffs, did not immediately respond to a request for comment.
Circuit Judges Sydney Thomas and M. Margaret McKeown and U.S. District Judge William Orrick of the Northern District of California, sitting by designation, joined in the unsigned opinion.
The MDL before Battaglia included about 1,500 plaintiffs and originally targeted not only Novo Nordisk but also AstraZeneca PLC's Amylin Pharmaceuticals, Eli Lilly and Co, and Merck & Co Inc. However, plaintiffs said in an August 2021 filing that an appeal as to those defendants was "not warranted," without providing further details.
Plaintiffs accused the companies of failing to warn of the drugs' risk of pancreatic cancer, after a 2013 study found that patients using them had precancerous pancreatic cells.
A California judge in April 2021 dismissed similar claims by about 500 plaintiffs in a coordinated state court proceeding.
The case is Adams v. Novo Nordisk A/S, 9th U.S. Circuit Court of Appeals, No. 21-55342.
For plaintiffs: Timothy Becker of Johnson Becker, Hunter Shkolnik of Napoli Shkolnik, Ryan Thompson of Watts Guerra and Tor Hoerman of TorHoerman Law
For Novo Nordisk: Loren Brown, Ilana Eisenstein, Lucas Przymusinski and Raymond Williams of DLA Piper
Read more:
Judge shuts down MDL claiming link between diabetes drugs and pancreatic cancer
Calif. judge tosses state claims that diabetes drugs cause pancreatic cancer
Our Standards: The Thomson Reuters Trust Principles.
Brendan Pierson reports on product liability litigation and on all areas of health care law. He can be reached at brendan.pierson@thomsonreuters.com.
Sign up to our legal newsletter for a smart look at the day's headlines concerning the practice of law.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved

source

Leave a Comment

Your email address will not be published.

Shopping Cart